Results for the First Quarter 2025
An exceptionally strong quarter for sales revenues, 20.1 % above the previous record, ending at MNOK 181.5. This is growth of 35.7 % compared to first quarter last year (MNOK 133.8).
Currency neutral sales of own products were up 29.9 % for the quarter.
Strong growth in all geographies with AMERICAS up 28.4 %, EMEA up 18.2 % and APAC up 62.6 %, currency neutral.
Third-party distributor sales in Scandinavia increased 41.2 % for the quarter.
Operating profit (EBIT) grew by 84.5 % and ended at MNOK 59.2 giving a 32.6 %EBIT margin (MNOK 32.1, 24.0 % margin)Recurring sales remained high, but strong capital sales reduce recurring sales in percent to 68 % (75 %) compared to same quarter last year.
Medistim strengthened its commercial operation by appointing a Chief Commercial Officer and a new VP Sales for AMERICAS. Solid cash position at quarter end with MNOK 183.4 and no interest-bearing liabilities. The General Meeting decided a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.6 (MNOK 82.4).
